Deciphera Pharmaceuticals announced its intent to file for regulatory approval with the FDA for its drug candidate ripretinib as a treatment for gastrointestinal stromal tumors. The filing will be supported by data from its late-stage trial, which resulted in an 85% decrease in risk for disease progress or mortality among GIST patients who had not responded to three prior therapies.
Deciphera to seek FDA approval for ripretinib for GIST
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.